Anuj Gaggar

Anuj Gaggar

Auto-generated profile, based on publicly available information

Anuj Gaggar

Assembly Biosciences, Inc. South San Francisco California USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJean Publicover
Jean Publicover
AGAnuj Gaggar
Anuj Gaggar
JJJillian M. Jespersen
Jillian M. Jespersen
UHUgur Halac
Ugur Halac
AJAudra J. Johnson
Audra J. Johnson
JBJody L. Baron
Jody L. Baron
Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.

21 April 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMilan J Sonneveld
Milan J Sonneveld
BHBettina Hansen
Bettina Hansen
WBWillem P Brouwer
Willem P Brouwer
HCHenry L-Y Chan
Henry L-Y Chan
TPTeerha Piratvisuth
Teerha Piratvisuth
SGSONIC-B Study Group
SONIC-B Study Group
Serum hepatitis B surface antigen (HBsAg) levels correlate with the duration of chronic hepatitis B virus (HBV) infection and may predict the extent of hepatic fibrosis. We analyzed data from the SONIC-B database, which contains data from 8 global randomized trials and 2 large hepatology centers. Relationship between HBsAg levels and presence of significant fibrosis (Ishak 3–4) or cirrhosis (Ishak 5–6) were explored, and clinically relevant cutoffs were identified to rule out cirrhosis. The dataset included 2779 patients: 1866 hepatitis B e antigen (HBeAg)-positive; 322 with cirrhosis. Among HBeAg-positive patients, lower HBsAg levels were associated with higher rates of significant fibrosis (odds ratio [OR], 0.419; P < .001) and cirrhosis (OR, 0.435; P < .001). No relationship was observed among HBeAg-negative patients. Among HBeAg-positive patients, genotype-specific HBsAg cutoffs had excellent negative predictive values (>97%) and low misclassification rates (≤7.1%) and may therefore have utility in ruling out cirrhosis. Diagnostic performance of the HBsAg cutoffs was comparable among patients in whom cirrhosis could not be ruled out with fibrosis 4 (FIB-4). Hepatitis B virus genotype-specific HBsAg cutoffs may have utility in ruling out presence of cirrhosis in HBeAg-positive patients with genotypes B, C, and D and can be an adjunct to FIB-4 to reduce the need for further testing.

15 November 2016 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SSSamir R. Shah
Samir R. Shah
PRP. N. Rao
P. N. Rao
SSShiv Kumar Sarin
Shiv Kumar Sarin
ACAbhijit Chowdhury
Abhijit Chowdhury
SBShobna Bhatia
Shobna Bhatia
RVRaj Vigna Venugopal
Raj Vigna Venugopal

1 May 2019 in Gastroenterology
Verified
Journal Article
Open access
SFSteven L. Flamm
Steven L. Flamm
ELEric Lawitz
Eric Lawitz
BBBrian Borg
Brian Borg
MCMichael Charlton
Michael Charlton
CLCharles Landis
Charles Landis
CHChristophe Hezode
Christophe Hezode

1 April 2015 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
JBJ. Bayliss
J. Bayliss
GRG. Rosenberg
G. Rosenberg
ATAlexander Thompson
Alexander Thompson
AGA. Gaggar
A. Gaggar
KKK. Kitrinos
K. Kitrinos
PRPeter Revill
Peter Revill

9 November 2026 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
EGEdward J. Gane
Edward J. Gane
CSChristian Schwabe
Christian Schwabe
NGNelli Ghicavii
Nelli Ghicavii
CTCristina Ticot
Cristina Ticot
KZKatie Zomorodi
Katie Zomorodi
AJAlina Jucov
Alina Jucov
Novel, well‐tolerated, short‐term therapeutics for chronic hepatitis B virus infection (cHBV) are needed. ABI‐4334 is a next‐generation capsid assembly modulator that targets the HBV core protein. The safety, tolerability, and pharmacokinetics of ABI‐4334 in healthy volunteers and participants with cHBV and antiviral effects in participants with cHBV were examined in two Phase 1 studies. Study 101 was a placebo‐controlled study of healthy volunteers that included four single‐ascending dose cohorts and two once‐daily multiple‐ascending dose cohorts randomized 6:2 (ABI‐4334:placebo), and one crossover food‐effect cohort randomized 3:3 (fed:fasted). Study 102 was a randomized, blinded, placebo‐controlled study where participants with cHBV were randomized 8:2 (ABI‐4334 [2 dose cohorts]:placebo). Overall, 54 healthy volunteers and 20 participants with cHBV were included in Studies 101 and 102, respectively. Most participants (75%) in Study 102 were hepatitis B e antigen (HBeAg) negative and generally had lower baseline HBV DNA and pregenomic RNA (pgRNA) levels. ABI‐4334 was well tolerated, with no treatment‐emergent serious adverse events (AEs) or treatment‐emergent AEs leading to study discontinuation. The mean ABI‐4334 plasma half‐life ranges were comparable across doses in both studies. Following multiple‐dose administration in participants with cHBV, the steady‐state mean plasma half‐life ranged from 17.5 to 27.5 h. HBV DNA declines were observed in both HBeAg‐positive ( n = 3) and ‐negative ( n = 13) participants across doses. Reductions in pgRNA were observed in participants with detectable pgRNA at baseline. ABI‐4334 was well tolerated, with pharmacokinetics and antiviral results supporting the continued development of ABI‐4334 as a monotherapy or component of novel combination regimens for cHBV. Trial Registration: Study 101 (NCT05569941). Study 102 (NCT06384131)